These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1499595)

  • 1. Clinical pharmacokinetics of the nifedipine/co-dergocrine combination in impaired liver and renal function.
    Kirch W; Nokhodian A; Halabi A; Weidinger G
    Eur J Drug Metab Pharmacokinet; 1992; 17(1):33-8. PubMed ID: 1499595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total and free steady-state plasma levels and pharmacokinetics of nifedipine in patients with terminal renal failure.
    van Bortel L; Böhm R; Mooij J; Schiffers P; Rahn KH
    Eur J Clin Pharmacol; 1989; 37(2):185-9. PubMed ID: 2792174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Metabolic consequences of long-term antihypertensive treatment with co-dergocrine mesylate/nifedipine in high age groups].
    Ritter MM; Richter WO; Schwandt P
    Arzneimittelforschung; 1992 Mar; 42(3):311-3. PubMed ID: 1497690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Nifedipine pharmacokinetics in liver cirrhosis patients after the administration of a single oral dose].
    Leucuţa SE; Grigorescu M; Dumitraşcu D
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1990; 42(2):185-90. PubMed ID: 1982192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of oral lidocaine and nifedipine in patients with liver cirrhosis.
    Tonsuwannont W; Praisontarangkul OA; Manorot M; Klangwarnwong D
    J Med Assoc Thai; 1996 May; 79(5):309-19. PubMed ID: 8708523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics of theophylline and enprofylline in patients with liver cirrhosis and in patients with chronic renal disease.
    Kraan J; Jonkman JH; Koëter GH; Gips CH; de Jong PE; van der Mark TW; Ekman I; de Zeeuw RA
    Eur J Clin Pharmacol; 1988; 35(4):357-62. PubMed ID: 3197743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration.
    Kleinbloesem CH; van Harten J; Wilson JP; Danhof M; van Brummelen P; Breimer DD
    Clin Pharmacol Ther; 1986 Jul; 40(1):21-8. PubMed ID: 3720176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine.
    Robertson DR; Waller DG; Renwick AG; George CF
    Br J Clin Pharmacol; 1988 Mar; 25(3):297-305. PubMed ID: 3358895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bunazosin in patients with impaired hepatic or renal function.
    Halabi A; Nokhodian A; Kirch W
    Eur J Drug Metab Pharmacokinet; 1993; 18(3):309-13. PubMed ID: 7908631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics of oral nifedipine--a population study.
    Renwick AG; Robertson DR; Macklin B; Challenor V; Waller DG; George CF
    Br J Clin Pharmacol; 1988 Jun; 25(6):701-8. PubMed ID: 3203042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of a new extended-release nifedipine formulation following a single oral dose, in human volunteers.
    Cainazzo MM; Pinetti D; Savino G; Bartiromo M; Forgione A; Bertolini A
    Drugs Exp Clin Res; 2005; 31(3):115-21. PubMed ID: 16033250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease.
    Marcantonio LA; Auld WH; Murdoch WR; Purohit R; Skellern GG; Howes CA
    Br J Clin Pharmacol; 1983 Feb; 15(2):245-52. PubMed ID: 6849758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of nifedipine after oral administration in chronic liver disease.
    Ene MD; Roberts CJ
    J Clin Pharmacol; 1987 Dec; 27(12):1001-4. PubMed ID: 3437063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nifedipine as an antihypertensive drug in patients with renal failure--pharmacokinetics and effects.
    Odar-Cederlöf I; Anderson P; Bondesson U
    J Intern Med; 1990 May; 227(5):329-37. PubMed ID: 2341826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A model study of bioequivalence of dissolved nifedipine from soft gelatin capsules].
    Menke G; Kausch M; Rietbrock N
    Arzneimittelforschung; 1988 Feb; 38(2):300-4. PubMed ID: 3370080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioavailability and pharmacokinetics of nifedipine administered by different routes in healthy volunteers.
    Palma-Aguirre JA; Rosas-Alcázar G; Rodríguez JM; León-Urrea F; Montoya-Cabrera MA
    Arch Invest Med (Mex); 1989; 20(2):129-35. PubMed ID: 2604495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of co-dergocrine mesilate/nifedipine compared to mefruside/nifedipine on circadian blood pressure in patients with essential hypertension.
    Kirsten R; Heller A; Heintz B; Nelson K
    J Hum Hypertens; 1990 Aug; 4(4):461-4. PubMed ID: 2258894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment.
    Malhotra BK; Schoenhard GL; de Kater AW; Friedmann N
    J Opioid Manag; 2015; 11(2):157-69. PubMed ID: 25901481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women.
    Jannuzzo MG; Poggesi I; Spinelli R; Rocchetti M; Cicioni P; Buchan P
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):475-81. PubMed ID: 15014897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Da-Chaihu-Tang alters the pharmacokinetics of nifedipine in rats and a treatment regimen to avoid this.
    He JX; Ohno K; Tang J; Hattori M; Tani T; Akao T
    J Pharm Pharmacol; 2014 Nov; 66(11):1623-30. PubMed ID: 24961584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.